Adverse Events After 13-Valent Pneumococcal Vaccination in Infants and Children: Insights from a Tertiary Care Hospital in Eastern India

Abstract

Background and Aims: The 13-valent pneumococcal conjugate vaccine (PCV13) is widely used to prevent invasive pneumococcal diseases in children. However, real-world safety data through active surveillance remain limited in many settings, including Eastern India. The aim of this study was to estimate the incidence, types, and risk factors of adverse events following immunization (AEFIs) with PCV13 among infants and young children in a tertiary care setting. Methods: A descriptive observational study was conducted at the Immunization Clinic of Calcutta National Medical College, Kolkata, from April to September 2024. Infants receiving any PCV13 dose were monitored for AEFIs using structured telephone follow-up at 24 hours, 48 hours, and 5–7 days post-vaccination. A standardized, pre-validated questionnaire was used for uniform data collection. Descriptive statistics, chi-square test, and reporting odds ratios were applied. Results: Out of 1,176 PCV13 doses given to 791 children, 569 AEFIs were reported in 435 children (48.38 per 100 doses). Fever (86.1%) was the most common reaction, followed by tenderness (16.87%), swelling (11.78%), and erythema (5.62%). Only one serious AEFI (0.09 per 100 doses) occurred. Younger age, preterm birth, and low birth weight were significant risk factors. AEFI incidence was highest after the first dose. Conclusions: PCV13 was generally safe and well tolerated. Most AEFIs were mild and self-limiting. The findings highlight the value of active surveillance and targeted caregiver education, especially for high-risk infants receiving their first dose.

References

1. 1.O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902.
2. 2.Rodgers GL, Klugman KP. The future of pneumococcal disease prevention. Vaccine. 2011;29(Suppl 3):C43–C48.
3. 3.Pittet LF,Posfay-Barbe KM.13-valent pneumococcal conjugate vaccines for children:a global public health priority. Clin Microbiol Infect. 2012;18(Suppl 5):25–36.
4. 4.Whitney CG, Farley MM, Hadler J, HarrisonLH,BennettNM,LynfieldR, et al.Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N Engl J Med.2003;348(18):1737–46.
5. 5.Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41.
6. 6.World Health Organization. 13-valent pneumococcal conjugate vaccines: WHO position paper. Wkly Epidemiol Rec. 2012;87(14):129–44.
7. 7.Varghese R, Veeraraghavan B, Jeyaraman Y, Kumar G, Arora NK, Balasubramanian S. Pneumococcal conjugate vaccine rollout in India: expectations and challenges.Indian J Med Microbiol. 2019;37(2):141–6.
8. 8.Huang LM, Chiang CS, Lee PI, Chiu CH, Chen JM, Liu CC, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Taiwan: a randomized, double-blind trial. Vaccine. 2012;30(12):2054–9.
9. 9.15.D’Angio CT. Active immunization in the preterm infant: special considerations and recommendations. Pediatrics. 2001;108(5):1269–74. 16.Kuter BJ, Ralph NM, Willis GA, Clements J, Fermon C, Black S, et al. Safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in infants and toddlers. J Pediatr. 2016;175:221–8.e8.